[go: up one dir, main page]

NO20076657L - Kombinasjonsterapi av cancer med AZD2171 og gemcitabin - Google Patents

Kombinasjonsterapi av cancer med AZD2171 og gemcitabin

Info

Publication number
NO20076657L
NO20076657L NO20076657A NO20076657A NO20076657L NO 20076657 L NO20076657 L NO 20076657L NO 20076657 A NO20076657 A NO 20076657A NO 20076657 A NO20076657 A NO 20076657A NO 20076657 L NO20076657 L NO 20076657L
Authority
NO
Norway
Prior art keywords
azd2171
gemcitabine
cancer
human
combination therapy
Prior art date
Application number
NO20076657A
Other languages
English (en)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0513778A external-priority patent/GB0513778D0/en
Priority claimed from GB0514347A external-priority patent/GB0514347D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20076657L publication Critical patent/NO20076657L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår en metode for å produsere en antiangiogen og/eller vaskulær permeabilitet-reduserende effekt hos et varmblodig dyr så som et menneske som eventuelt behandles med ioniserende stråling, spesielt en metode for behandling av kreft, spesielt kreft som involverer en fast tumor, som omfatter administrering av AZD2171 i kombinasjon med gemcitabin; et farmasøytisk preparat omfattende AZD2171 og gemcitabin; et kombinasjonsprodukt omfattende AZD2171 og gemcitabin for anvendelse ved en metode for behandling av en menneske- eller dyrekropp ved terapi; et sett omfattende AZD2171 og gemcitabin; anvendelse av AZD2171 og gemcitabin ved fremstilling av et medikament for anvendelse for å produsere en antiangiogen og/eller vaskulær permeabilitet-reduserende effekt hos et varmblodig dyr så som et menneske som eventuelt behandles med ioniserende stråling.
NO20076657A 2005-07-06 2007-12-28 Kombinasjonsterapi av cancer med AZD2171 og gemcitabin NO20076657L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0513778A GB0513778D0 (en) 2005-07-06 2005-07-06 Combination therapy
GB0514347A GB0514347D0 (en) 2005-07-13 2005-07-13 Combination therapy
PCT/GB2006/002462 WO2007003933A2 (en) 2005-07-06 2006-07-03 Combination therapy of cancer with azd2171 and gemcitabine

Publications (1)

Publication Number Publication Date
NO20076657L true NO20076657L (no) 2008-04-03

Family

ID=37005849

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076657A NO20076657L (no) 2005-07-06 2007-12-28 Kombinasjonsterapi av cancer med AZD2171 og gemcitabin

Country Status (12)

Country Link
US (1) US20090176731A1 (no)
EP (1) EP1901754A2 (no)
JP (1) JP2009500384A (no)
KR (1) KR20080031029A (no)
AU (1) AU2006264620B2 (no)
BR (1) BRPI0612397A2 (no)
CA (1) CA2614002A1 (no)
IL (1) IL188513A0 (no)
MX (1) MX2007016497A (no)
NO (1) NO20076657L (no)
NZ (1) NZ564189A (no)
WO (1) WO2007003933A2 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
JP2007530517A (ja) * 2004-03-23 2007-11-01 アストラゼネカ アクチボラグ 組合せ療法
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
KR20080077678A (ko) * 2005-12-22 2008-08-25 아스트라제네카 아베 Ａｚｄ2171 및 페메트렉시드의 조합물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
JP2007530517A (ja) * 2004-03-23 2007-11-01 アストラゼネカ アクチボラグ 組合せ療法
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
BRPI0511065A (pt) * 2004-06-04 2007-12-26 Pfizer Prod Inc método para tratar crescimento de célula anormal
CA2579067A1 (en) * 2004-09-27 2006-04-06 Astrazeneca Ab Cancer combination therapy comprising azd2171 and imatinib
CA2633211A1 (en) * 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
KR20080077678A (ko) * 2005-12-22 2008-08-25 아스트라제네카 아베 Ａｚｄ2171 및 페메트렉시드의 조합물
CN101678001A (zh) * 2007-04-13 2010-03-24 阿斯利康(瑞典)有限公司 包含azd2171和azd6244或mek-抑制剂ⅱ的组合治疗

Also Published As

Publication number Publication date
WO2007003933A3 (en) 2007-12-27
AU2006264620A1 (en) 2007-01-11
KR20080031029A (ko) 2008-04-07
NZ564189A (en) 2011-04-29
US20090176731A1 (en) 2009-07-09
AU2006264620B2 (en) 2009-10-22
EP1901754A2 (en) 2008-03-26
WO2007003933A2 (en) 2007-01-11
IL188513A0 (en) 2008-08-07
BRPI0612397A2 (pt) 2011-02-22
CA2614002A1 (en) 2007-01-11
JP2009500384A (ja) 2009-01-08
MX2007016497A (es) 2008-03-07

Similar Documents

Publication Publication Date Title
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
NO20072167L (no) Kombinasjon omfattende ZD6474 og et antiandrogen
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
BR0309226A (pt) Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável
NO20064753L (no) Kombinasjonsterapi
NO20056170L (no) Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839
NO20064755L (no) Kombinasjonsterapi
NO20064754L (no) Kombinasjonsterapi
NO20056171L (no) Kombinasjonsterapi
NO20051601L (no) Kombinasjonsterapi med gemcitabin og zd6126

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application